• Je něco špatně v tomto záznamu ?

Markers of endothelial activation in preeclampsia

M Prochazka, J Prochazkova, M Lubusky, R Pilka, J Ulehlova, I Michalec, P Polak, M Kacerovsky, L Slavik

. 2015 ; 61 (1-2) : 39-46.

Jazyk angličtina Země Německo

Perzistentní odkaz   https://www.medvik.cz/link/bmc18034565

Grantová podpora
NT14394 MZ0 CEP - Centrální evidence projektů

BACKGROUND: The study aimed at finding a laboratory approach to detect endothelial damage in normal pregnancy as well as in pregnancy complicated by preeclampsia using selected markers of endothelial activation. MATERIALS: A total of 403 healthy pregnant women without a history of deep vein thrombosis and/or hypertension were prospectively studied. From all women, venous blood was collected before the end of the 1st trimester, between weeks 24 and 28 of gestation, and in the 3rd trimester (weeks 34-36). Assays of tissue plasminogen activator, plasminogen activator inhibitor-1, von Willebrand factor activity and antigen, thrombomodulin, endothelial protein C receptor, and endothelial microparticles activated by TF were performed. RESULTS: When comparing women who developed preeclampsia during pregnancy (the average levels were 23.41 mug/L, 34.33 mug/L, and 53.56 mug/L in the 1st, 2nd, and 3rd trimesters, respectively) with healthy pregnant women (the average levels were 19.05 mug/L, 28.47 mug/L, and 39.86 mug/L in the 1st, 2nd, and 3rd trimesters, respectively) significant differences in the levels of thrombomodulin were found in all three trimesters. By contrast, no statistically significant differences in the levels of vWF (both antigen and activity), t-PA, EPCR, EMPs, MMP-2, MMP-9, and TIMP-9 were found in any trimesters in the same group. CONCLUSIONS: Pregnancy and preeclampsia strongly influence the levels of studied markers. The findings of this work confirm the possible predictive potential of thrombomodulin and PA-1.

000      
00000naa a2200000 a 4500
001      
bmc18034565
003      
CZ-PrNML
005      
20190104103724.0
007      
ta
008      
181010s2015 gw f 000 0|eng||
009      
AR
035    __
$a (PubMed)25807636
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Procházka, Martin, $d 1970- $7 xx0019288 $u Department of Obsterics and Gynecology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
245    10
$a Markers of endothelial activation in preeclampsia / $c M Prochazka, J Prochazkova, M Lubusky, R Pilka, J Ulehlova, I Michalec, P Polak, M Kacerovsky, L Slavik
520    9_
$a BACKGROUND: The study aimed at finding a laboratory approach to detect endothelial damage in normal pregnancy as well as in pregnancy complicated by preeclampsia using selected markers of endothelial activation. MATERIALS: A total of 403 healthy pregnant women without a history of deep vein thrombosis and/or hypertension were prospectively studied. From all women, venous blood was collected before the end of the 1st trimester, between weeks 24 and 28 of gestation, and in the 3rd trimester (weeks 34-36). Assays of tissue plasminogen activator, plasminogen activator inhibitor-1, von Willebrand factor activity and antigen, thrombomodulin, endothelial protein C receptor, and endothelial microparticles activated by TF were performed. RESULTS: When comparing women who developed preeclampsia during pregnancy (the average levels were 23.41 mug/L, 34.33 mug/L, and 53.56 mug/L in the 1st, 2nd, and 3rd trimesters, respectively) with healthy pregnant women (the average levels were 19.05 mug/L, 28.47 mug/L, and 39.86 mug/L in the 1st, 2nd, and 3rd trimesters, respectively) significant differences in the levels of thrombomodulin were found in all three trimesters. By contrast, no statistically significant differences in the levels of vWF (both antigen and activity), t-PA, EPCR, EMPs, MMP-2, MMP-9, and TIMP-9 were found in any trimesters in the same group. CONCLUSIONS: Pregnancy and preeclampsia strongly influence the levels of studied markers. The findings of this work confirm the possible predictive potential of thrombomodulin and PA-1.
590    __
$a bohemika - dle Pubmed
650    02
$a dospělí $7 D000328
650    02
$a CD antigeny $x krev $7 D015703
650    12
$a biologické markery $x krev $7 D015415
650    02
$a studie případů a kontrol $7 D016022
650    02
$a endoteliální receptor proteinu C $7 D000074283
650    02
$a cévní endotel $x patofyziologie $7 D004730
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a inhibitor aktivátoru plazminogenu 1 $x krev $7 D017395
650    12
$a preeklampsie $x krev $x patofyziologie $7 D011225
650    02
$a těhotenství $7 D011247
650    12
$a první trimestr těhotenství $x krev $7 D011261
650    02
$a prospektivní studie $7 D011446
650    02
$a receptory buněčného povrchu $x krev $7 D011956
650    02
$a referenční hodnoty $7 D012016
650    02
$a trombomodulin $x krev $7 D018180
650    02
$a tkáňový aktivátor plazminogenu $x krev $7 D010959
650    02
$a mladý dospělý $7 D055815
650    02
$a von Willebrandův faktor $x metabolismus $7 D014841
700    1_
$a Procházková, Jana $7 xx0067433 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Ľubušký, Marek, $d 1970- $7 xx0073925 $u Department of Obsterics and Gynecology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Pilka, Radovan, $d 1964- $7 xx0042227 $u Department of Obsterics and Gynecology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Úlehlová, Jana $7 xx0117725 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Michalec, Igor $7 _AN048855 $u Department of Hemato-Oncology, University Hospital Ostrava, Czech Republic
700    1_
$a Polák, Petr, $d 1960- $7 xx0070573 $u Department of Obsterics and Gynecology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Kacerovský, Marian $7 xx0096559 $u Department of Obsterics and Gynecology, Charles University, Hradec Králové, Czech Republic
700    1_
$a Slavík, Luděk $7 xx0081908 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
773    0_
$t Clinical Laboratory $x 1433-6510 $g Roč. 61, č. 1-2 (2015), s. 39-46 $p Clin Lab $w MED00009480
773    0_
$p Clin Lab $g 61(1-2):39-46, 2015 $x 1433-6510
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20181010160656 $b ABA008
991    __
$a 20190104103920 $b ABA008
999    __
$a ok $b bmc $g 1341249 $s 1031562
BAS    __
$a 3
BMC    __
$a 2015 $b 61 $c 1-2 $d 39-46 $x MED00009480 $i 1433-6510 $m Clinical laboratory
GRA    __
$a NT14394 $p MZ0
LZP    __
$a NLK 2018/lp

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...